Imiquimod and the treatment of cutaneous T-cell proliferative diseases: at the threshold.
Herbert
W Clark
WC
Department of Dermatology, The University of Medicine & Dentistry of New Jersey-New Jersey Medical School, Newark, NJ 07103, USA. lamberwc@umdnj.edu
D000634:Aminoquinolines / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D000077271:Imiquimod; D016410:Lymphoma, T-Cell, Cutaneous / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D020714:Maximum Tolerated Dose; D011379:Prognosis; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D016896:Treatment Outcome
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D000077271:Imiquimod